Phase 1b study of ARN-509 combined with everolimus in abiraterone-resistant CPRC at baseline and progression - Stand Up To Cancer

Blog

Posted October 14, 2019

Phase 1b study of ARN-509 combined with everolimus in abiraterone-resistant CPRC at baseline and progression

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.